KDR and Hypertension: The occurrence of hypertension connected to different VEGFR-TKIs was also examined, and the results showed that sunitinib (RR, 7.91; 95% CI, 5.40-11.57), pazopanib (RR, 7.58; 95% CI, 3.08-18.62), cabozantinib (RR, 7.13; 95% CI, 2.97-17.15), vandetanib (RR, 5.25; 95% CI, 4.12-6.70), motesanib (RR, 4.02; 95% CI, 2.83-5.70), regorafenib (RR, 3.96; 95% CI, 2.72-5.79), cediranib (RR, 3.72; 95% CI, 2.95-4.70), and sorafenib (RR, 3.07; 95% CI, 2.43-3.87) led to a remarkable increment in the risk for all-grade hypertensive events.